NGF in experimental models of Parkinson disease.
We have now applied the enzyme immunoassay using anti-NGF monoclonal antibody (MAb) 27/21 and a blocking test validating the specificity of the immunoreactivity for NGF in serum samples to examine NGF levels in normal rat sera, hemiparkinsonian rat sera, normal monkey sera, and MPTP-treated monkey sera. The levels of NGF in treated animals showed reductions when compared with serum from normal animals. The NGF level alterations observed in lesioned animals and in human parkinsonian patients evidence a relationship between this neurotrophic factor and the neurodegenerative changes observed in Parkinson disease (PD).
Lorigados
L
L
Centro Internacional de Restauración Neurológica, Habana, Cuba.
Alvarez
P
P
Pavón
N
N
Serrano
T
T
Blanco
L
L
Macías
R
R
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D015415:Biomarkers / Q000097:blood; D006801:Humans; D007124:Immunoenzyme Techniques; D008251:Macaca; D008297:Male; D009414:Nerve Growth Factors / Q000097:blood*; D010300:Parkinson Disease / Q000097:blood*; D010302:Parkinson Disease, Secondary / Q000097:blood* / Q000139:chemically induced; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D009414:Nerve Growth Factors; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine